Neogen Chemicals Limited and Livent Corporation announced today that Neogen will acquire a 100% stake in BuLi Chemicals India Pvt. Ltd (BuLi Chem) from Livent. BuLi Chem owns the technology for producing N Butyl Lithium and other organolithium products from lithium metal, which are key reagents for the lithiation reaction used in the production of a variety of complex pharmaceutical and agrochemical intermediates. BuLi Chem manufactures and supplies N Butyl Lithium to several leading pharmaceutical and agrochemical companies in India and around the world, and has built one of the few commercial facilities for this chemistry outside of China.
“We are pleased to be acquiring BuLi Chem, which houses the Indian operations of Livent USA Corp – one of the global leaders in speciality lithium technology,” said Dr. Harin Kanani, Managing Director at Neogen Chemicals. We are delighted to welcome to the Neogen family the employees of BuLi Chem, who have over a decade of experience in handling Organo Lithium Chemistry. They have created one of the few facilities for this chemistry outside of China, with a proven track record of safety and sustainability.
Organo Lithium compounds are important in the production of several critical pharmaceutical and agrochemical intermediates, and we are pleased to continue our collaboration and meet this critical societal need. The ability to recycle Lithium, as well as the ability to use highly reactive Lithium metal and manufacture N Butyl Lithium and other Organo Lithium derivatives in-house, will provide a significant competitive advantage to our existing as well as under-development Pharma Advanced intermediates and CSM projects, further enhancing our ability to provide value-added innovative solutions to our global customers.”